MCMassimiliano Cazzaniga

Massimiliano Cazzaniga

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Massimiliano Cazzaniga has a total of 53 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

    • 17 November 2026
    • Published by MDPI AG in Current Oncology
      • Vol. 33  (11) , 710
      • https://doi.org/10.3390/curroncol33110710
    Open Access

    Microbiota-Driven Mechanisms in Endometrial Cancer Pathogenesis: Focus on Lynch Syndrome

    by Silvia Actis, Massimiliano Cazzaniga, Marta D’Alonzo, Gaetano Perrini, Margherita Giorgi, Luca Pace, Maria Pascotto, Beatrice Campigotto, Annamaria Ferrero, Valentina Elisabetta Bounous

    Lynch syndrome is the most common hereditary syndrome predisposing to endometrial cancer, but the mechanisms contributing to tumor development remain incompletely understood. This review aimed to summarise current evidence on the composition and potential pathogenic role of the microbiota in Lynch syndrome-associated endometrial cancer and to explore its clinical implications. A systematic literature search of PubMed/MEDLINE and Embase was conducted between October and November 2025 using predefined terms related to microbiota, carcinogenesis, endometrial cancer, and Lynch syndrome. Available evidence suggests that alterations in the microbiota may contribute to carcinogenesis through chronic inflammation, immune modulation, metabolic changes, and bacterial genotoxicity. Studies in Lynch syndrome carriers with endometrial or colorectal cancer report an increased abundance of potentially pro-inflammatory Gram-negative bacteria, including Bacteroides fragilis and Fusobacterium nucleatum, together with a reduction in short-chain fatty acid-producing bacteria such as Faecalibacterium, Blautia, and Butyrivibrio. Microbial metabolites, including butyrate, may have protective effects, whereas bacterial β-glucuronidase activity may increase estrogen bioavailability and contribute to a tumor-promoting environment. Emerging evidence also suggests that the microbiota may influence treatment response and toxicity. Overall, current evidence supports a potential role for the microbiota in Lynch syndrome-associated endometrial carcinogenesis, although data remain limited. Further studies are needed to determine whether microbiota profiling could contribute to risk stratification, prevention, and personalized therapeutic strategies.

  • Open Access

    RETRACTED: Bellomo et al. Effect of Bifidobacterium bifidum Supplementation in Newborns Born from Cesarean Section on Atopy, Respiratory Tract Infections, and Dyspeptic Syndromes: A Multicenter, Randomized, and Controlled Clinical Trial. Microorganisms 2024, 12, 1093

    by Anna Rita Bellomo, Giulia Rotondi, Prudenza Rago, Silvia Bloise, Luigi Di Ruzza, Annamaria Zingoni, Susanna Di Valerio, Eliana Valzano, Francesco Di Pierro, Massimiliano Cazzaniga, et al.

    The journal retracts the article, “Effect of Bifidobacterium bifidum Supplementation in Newborns Born from Cesarean Section on Atopy, Respiratory Tract Infections, and Dyspeptic Syndromes: A Multicenter, Randomized, and Controlled Clinical Trial”

  • Open Access

    The Role of Targeted Microbiota Therapy in the Prevention and Management of Puerperal Mastitis

    by Mariarosaria Matera, Chiara Maria Palazzi, Alexander Bertuccioli, Francesco Di Pierro, Nicola Zerbinati, Massimiliano Cazzaniga, Aurora Gregoretti, Ilaria Cavecchia

    Mastitis, an inflammatory condition of the breast, significantly affects breastfeeding women and can lead to the early cessation of lactation. This article explores the pathophysiology of mastitis, distinguishing between acute mastitis (AM) and subacute mastitis (SAM), with a focus on the microbial dynamics involved. AM is primarily associated with Staphylococcus aureus, while SAM is linked to a dysbiotic milk microbiota characterized by an imbalance of microbial species, including increased levels of opportunistic pathogens. The role of inflammation and the gut–breast axis in the development of mastitis are discussed, emphasizing the importance of maintaining a healthy microbiota. Recent studies highlight the potential of probiotics as a preventive and therapeutic measure against mastitis, showing promising results in reducing incidence and recurrence. However, further research is necessary to optimize probiotic strains, dosages, and treatment protocols. This review underscores the need for a comprehensive understanding of the microbiological, immunological, and inflammatory factors involved in mastitis to develop effective prevention and treatment strategies.


  • Open Access

    Irritable Bowel Syndrome with Diarrhea (IBS-D): Effects of Clostridium butyricum CBM588 Probiotic on Gastrointestinal Symptoms, Quality of Life, and Gut Microbiota in a Prospective Real-Life Interventional Study

    by Francesco Di Pierro, Fabrizio Ficuccilli, Laura Tessieri, Francesca Menasci, Chiara Pasquale, Amjad Khan, Fazle Rabbani, Nazia Mumtaz Memon, Massimiliano Cazzaniga, Alexander Bertuccioli, et al.

    Diarrhea-predominant irritable bowel syndrome (IBS-D) is a functional gastrointestinal disorder characterized by altered motility, abdominal pain, and dysbiosis—particularly reduced biodiversity and a lower abundance of butyrate-producing bacteria. Strategies that modulate the gut microbiota may offer therapeutic benefit. Clostridium butyricum (C. butyricum) CBM588 is a butyrate-producing probiotic with immunomodulatory properties and potential efficacy in treating gastrointestinal disorders. This pragmatic, prospective, open-label, single-arm interventional study assessed the clinical, microbial, and safety-related effects of an 8-week CBM588 supplementation, along with a low-fiber and low-residue diet, in 205 patients with IBS-D who attended Quisisana Nursing Home Hospital, Rome, Italy, between November 2024 and February 2025. The primary outcomes included the global symptom response, the Bristol Stool Scale (BSS), stool frequency, diarrhea episodes, abdominal pain (severity and frequency), bloating, bowel dissatisfaction, quality of life (QoL), safety, and treatment tolerability—measured using the IBS Symptom Severity Scale (IBS-SSS) and a standardized tolerability scale. CBM588, in patients treated with a low-fiber and low-residue diet, significantly improved all clinical endpoints, with a >80% reduction in diarrhea episodes; ~60% reductions in stool frequency and abdominal pain; and >50% improvements in bloating, bowel dissatisfaction, and QoL. Treatment was well tolerated (mean tolerability score 8.95 ± 0.88), with >95% adherence, and no serious adverse events were reported. The secondary outcomes included changes in gut microbiota. In a subset of patients, 16S rRNA gene sequencing showed increased α-diversity and enrichment of butyrate-producing genera (Agathobacter, Butyricicoccus, Coprococcus), which correlated with symptom improvement. Bloating increased in some patients, possibly related to fermentation activity. These findings support the C. butyricum CBM588 probiotic strain as a safe, well-tolerated, and microbiota-targeted intervention for IBS-D. Randomized controlled trials are warranted to confirm efficacy.


  • Open Access

    Effects of Melissa officinalis Phytosome on Sleep Quality: Results of a Prospective, Double-Blind, Placebo-Controlled, and Cross-Over Study

    by Francesco Di Pierro, Davide Sisti, Marco Rocchi, Annalisa Belli, Alexander Bertuccioli, Massimiliano Cazzaniga, Chiara Maria Palazzi, Maria Laura Tanda, Nicola Zerbinati

    Background: Melissa officinalis standardised extracts, characterised by the presence of hydroxycinnamic acids, have been experimentally demonstrated to be endowed with anti-anxiety and anti-insomnia pharmacological actions. These effects, probably attributable, at least in part, to the role played by rosmarinic acid on GABA-T, have not always been observed in a reproducible manner in humans, perhaps due to the poor bioavailability of these compounds. Methods: as nutraceuticals and botanicals could be an alternative option to prescription medications for alleviating symptoms of mild anxiety and insomnia, we have verified in a prospective, double-blind, placebo-controlled, and cross-over study the supporting role on sleep quality played by a Melissa officinalis highly standardised extract, formulated as Phytosome™ (MOP) to improve the oral bioavailability of its active polyphenolic components. Results: results showed a significant reduction in the ISI score in the treated group, with an average of 6.8 ± 4.1 compared to 9.7 ± 3.7 in the placebo group, indicating a significant reduction of 2.9 points (p = 0.003). The SWS phase duration increased by an average of 15%, while the REM phase decreased by 10%. Additionally, 87% of participants in the treated group reported improved sleep quality, compared to 30% in the placebo group, with significant differences measured by chi-square test (χ2(4) = 21.01, p = 0.0003), highlighting the effects due to Melissa officinalis L. No significant changes in physical activity or anxiety levels were observed. Conclusions: these findings suggest that MOP may represent a natural and safe alternative to traditional pharmacological treatments for insomnia.


  • Open Access

    Assessment of Perceived Effort Through On-Field Hydration Monitoring: A Case Analysis

    by Alexander Bertuccioli, Roberto Cannataro, Davide Sisti, Giordano Bruno Zonzini, Massimiliano Cazzaniga, Marco Cardinali, Francesco Di Pierro, Aurora Gregoretti, Nicola Zerbinati, Mariarosaria Matera, et al.

    This case report examines the correlation between hydration, weight variation, and perceived effort in a 43-year-old amateur athlete during a self-supported 81.5 km crossing of Death Valley, completed over 3 days with significant elevation changes. Studies have shown that a body mass loss greater than 2–3% can lead to an increased perception of effort and a decline in performance. Specifically, during passive and active heat exposures, the average body mass loss was found to be 1.4 ± 0.3% and 4.1 ± 0.7%, respectively. Salivary osmolarity has demonstrated a sensitivity of 86% and specificity of 91% in diagnosing dehydration of ≥ 2%, suggesting its potential as a non-invasive indicator of hydration status. The subject monitored their own body weight, hydration (via salivary osmolarity), and perceived effort using a rate of perceived exertion (RPE) scale. Nutritional intake included isocaloric meals and nutritional bars, and hydration was managed using water and a hydroelectrolytic solution. Key bioimpedance parameters were measured to assess body composition and hydration status. A progressive decrease in body weight correlated with an increase in perceived effort (RPE score) and salivary osmolarity. Resistance (Rx) remained stable, while reactance (Xc) showed a biphasic trend and was inversely correlated with the sodium/potassium ratio (NAK). There were significant linear correlations between perceived effort and both weight loss and salivary osmolarity, indicating that salivary osmolarity is a potential early predictor of these changes. The findings highlight a linear correlation between weight loss, perceived effort, and salivary osmolarity, suggesting that monitoring salivary osmolarity would be useful for the field assessment of hydration and exertion. Further research with larger populations is necessary to validate these observations.

  • Open Access

    A Controlled, Retrospective, Single-Center Study to Evaluate the Role of a Probiotic Mixture Administered during Pregnancy in Reducing Streptococcus Agalactiae Swab Positivity and the Frequency of Premature Rupture of Amniochorionic Membranes

    by Maurizio Arduini, Elena Laurenti, Massimiliano Cazzaniga, Alexander Bertuccioli, Ilaria Cavecchia, Mariarosaria Matera, Nicola Zerbinati, Francesco Di Pierro

    Intrapartum antibiotic prophylaxis, considered able to prevent streptococcal transmission from mother to newborn and its severe negative consequences, leads to microbiota dysbiosis, described as having a negative impact on well-being in both elements of the dyad. Enterococcus faecium L3 is a probiotic strain capable of exerting strong antagonistic activity against most streptococci, including S. agalactiae, due to the production of bacteriocins (known as enterocins A and B). A proprietary probiotic mixture containing the strain L3 demonstrated, in 2016, a significant reduction in episodes of PROM in pregnant women, with a less-than-expected effect on the vaginal–rectal presence of the pathogen S. agalactiae. With the aim of confirming the role exerted by the probiotic mixture in PROM episodes and to better understand the value of its impact on the clinical detection of S. agalactiae, we have retrospectively analyzed the results obtained in 125 L3-treated (over 12 weeks) women versus 125 untreated controls. Despite some limitations, our analysis has confirmed the role exerted by the probiotic in significantly reducing the following: (1) episodes of PROM, (2) vaginal–rectal positivity for S. agalactiae, and (3) the need to administer intrapartum antibiotics for prophylaxis. It likely also suggests operating using a cultural method very specific to S. agalactiae when testing women who were administered an Enterococcus-based probiotic.


  • Open Access

    The Anti-Constipation Effect of Bifidobacterium Longum W11 Is Likely Due to a Key Genetic Factor Governing Arabinan Utilization

    by Francesco Di Pierro, Nicola Zerbinati, Massimiliano Cazzaniga, Alexander Bertuccioli, Chiara Maria Palazzi, Ilaria Cavecchia, Mariarosaria Matera, Edoardo Labrini, Valeria Sagheddu, Sara Soldi

    Recent investigations have highlighted, both experimentally and clinically, that probiotic strains equipped with arabinofuranosidase, in particular abfA and abfB, favor regular intestinal motility, thus counteracting constipation. By analyzing the gene expression and the proliferative response in the presence of arabinan of the probiotic B. longum W11, a strain previously validated as an anti-constipation probiotic, we have speculated that its response mechanism to arabinan can effectively explain its clinical action. Our approach could be used in the future to select probiotics endowed with arabinofuranosidase-related anti-constipation effects.


  • Open Access

    The Role of Short-Chain Fatty Acids, Particularly Butyrate, in Oncological Immunotherapy with Checkpoint Inhibitors: The Effectiveness of Complementary Treatment with Clostridium butyricum 588

    by Massimiliano Cazzaniga, Marco Cardinali, Francesco Di Pierro, Giordano Bruno Zonzini, Chiara Maria Palazzi, Aurora Gregoretti, Nicola Zerbinati, Luigina Guasti, Maria Rosaria Matera, Ilaria Cavecchia, et al.

    The discovery of immune checkpoints (CTLA-4, PD-1, and PD-L1) and their impact on the prognosis of oncological diseases have paved the way for the development of revolutionary oncological treatments. These treatments do not combat tumors with drugs “against” cancer cells but rather support and enhance the ability of the immune system to respond directly to tumor growth by attacking the cancer cells with lymphocytes. It has now been widely demonstrated that the presence of an adequate immune response, essentially represented by the number of TILs (tumor-infiltrating lymphocytes) present in the tumor mass decisively influences the response to treatments and the prognosis of the disease. Therefore, immunotherapy is based on and cannot be carried out without the ability to increase the presence of lymphocytic cells at the tumor site, thereby limiting and nullifying certain tumor evasion mechanisms, particularly those expressed by the activity (under positive physiological conditions) of checkpoints that restrain the response against transformed cells. Immunotherapy has been in the experimental phase for decades, and its excellent results have made it a cornerstone of treatments for many oncological pathologies, especially when combined with chemotherapy and radiotherapy. Despite these successes, a significant number of patients (approximately 50%) do not respond to treatment or develop resistance early on. The microbiota, its composition, and our ability to modulate it can have a positive impact on oncological treatments, reducing side effects and increasing sensitivity and effectiveness. Numerous studies published in high-ranking journals confirm that a certain microbial balance, particularly the presence of bacteria capable of producing short-chain fatty acids (SCFAs), especially butyrate, is essential not only for reducing the side effects of chemoradiotherapy treatments but also for a better response to immune treatments and, therefore, a better prognosis. This opens up the possibility that favorable modulation of the microbiota could become an essential complementary treatment to standard oncological therapies. This brief review aims to highlight the key aspects of using precision probiotics, such as Clostridium butyricum, that produce butyrate to improve the response to immune checkpoint treatments and, thus, the prognosis of oncological diseases.


  • Open Access

    RETRACTED: Effect of Bifidobacterium bifidum Supplementation in Newborns Born from Cesarean Section on Atopy, Respiratory Tract Infections, and Dyspeptic Syndromes: A Multicenter, Randomized, and Controlled Clinical Trial

    by Anna Rita Bellomo, Giulia Rotondi, Prudenza Rago, Silvia Bloise, Luigi Di Ruzza, Annamaria Zingoni, Susanna Di Valerio, Eliana Valzano, Francesco Di Pierro, Massimiliano Cazzaniga, et al.

    Cesarean section is considered a possible trigger of atopy and gut dysbiosis in newborns. Bifidobacteria, and specifically B. bifidum, are thought to play a central role in reducing the risk of atopy and in favoring gut eubiosis in children. Nonetheless, no trial has ever prospectively investigated the role played by this single bacterial species in preventing atopic manifestations in children born by cesarean section, and all the results published so far refer to mixtures of probiotics. We have therefore evaluated the impact of 6 months of supplementation with B. bifidum PRL2010 on the incidence, in the first year of life, of atopy, respiratory tract infections, and dyspeptic syndromes in 164 children born by cesarean (versus 249 untreated controls). The results of our multicenter, randomized, and controlled trial have shown that the probiotic supplementation significantly reduced the incidence of atopic dermatitis, upper and lower respiratory tract infections, and signs and symptoms of dyspeptic syndromes. Concerning the gut microbiota, B. bifidum supplementation significantly increased α-biodiversity and the relative values of the phyla Bacteroidota and Actinomycetota, of the genus Bacteroides, Bifidobacterium and of the species B. bifidum and reduced the relative content of Escherichia/Shigella and Haemophilus. A 6-month supplementation with B. bifidum in children born by cesarean section reduces the risk of gut dysbiosis and has a positive clinical impact that remains observable in the following 6 months of follow-up.